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E-mail address: zhut@ustc.edu.cn (T. Zhu).Metastasis is the leading cause of death in patients with hepatocellular carcinoma (HCC) and
microRNAs have been implicated to inﬂuence this process. Emerging evidence indicates that miR-
198 is down-regulated in HCC compared to normal liver parenchyma, but the functional roles of
miR-198 in HCC cells remains unexplored. Herein, we show that miR-198 directly targets c-MET
via its 30UTR. Forced expression of miR-198 decreased c-MET expression at both mRNA and protein
levels and consequently diminished HGF induced phosphorylation of p44/42 MAPK in HCC cells.
Forced expression of miR-198 inhibited HGF promotion of HCC cell migration and invasion in a c-
MET dependent manner. In conclusion, we have identiﬁed miR-198 as a novel suppressor of HCC cell
invasion by negative regulation of the HGF/c-MET pathway.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most lethal hu-
man cancers with increasing global incidence. It is the third most
common cause of cancer-related death [1,2]. Despite improvement
in treatment over the past few decades, relapse or tumor metasta-
sis is frequently observed and the 5-year survival rate of patients
with HCC is still quite low [1,2]. The molecular pathogenesis of
HCC is complicated and remains poorly deﬁned. Dysregulation of
a number of protein-coding genes and their associated signaling
pathways has been reported in HCC, such as hepatocyte growth
factor (HGF)/c-MET, WNT/beta-Catenin, and insulin-like growth
factor [3–5], the roles and potential mechanisms of miRNAs in
HCC are largely unexplored.
miRNAs are small non-coding RNA molecules ranging in size
from 20 to 25 nucleotides which regulate gene expression by di-
rectly degrading messenger RNA (mRNA) or repressing protein
translation [6]. Emerging evidence has established miRNAs as piv-
otal players in the initiation, promotion, and progression of various
human cancers. miRNAs have been identiﬁed that function as clas-
sical oncogenes or tumor suppressor genes [7–9]. miRNAs may
represent a novel and attractive therapeutic strategy as one miRNAchemical Societies. Published by E
oratory for Physical Sciences
of Science and Technology of
a. Fax: +86 551 3601505.could simultaneously regulate the expression of hundreds of dif-
ferent genes. Various recent different studies have shown that
miRNAs are often deregulated in HCC and that several deregulated
miRNAs (e.g., miR-21, miR-122, miR-101, miR-194, miR-151, miR-
191, miR-221 and miR-222) may possess important roles in hepa-
tic cancer progression and directly contribute to cell proliferation,
apoptosis and metastasis of HCC [10–18].
Herein, we show that miR-198 negatively modulates c-MET
expression and subsequently diminishes HGF stimulated migration
and invasion of HCC cells. Forced expression of miR-198 may
therefore provide a therapeutic strategy for patients with HCC.
2. Materials and methods
2.1. Cell culture
HepG2, Hep3B, QGY-7701, QGY-7703, BEL-7404 and SMMC-
7721 cells were derived from patients with HCC. QGY-7701,
QGY-7703, BEL-7404 and SMMC-7721 were purchased from the
cell bank of Shanghai Institute of Cell Biology; HepG2 and Hep3B
cells were purchased from American Type Culture Collection.
QGY-7701, QGY-7703, BEL-7404 and SMMC-7721 were main-
tained in DMEM plus 10% heat-inactivated fetal bovine serum
HepG2 and Hep3B were maintained in DMEM/F12 plus 10% heat-
inactivated fetal bovine serum. All cells were maintained in a
humidiﬁed incubator at 37 C and 5% CO2.lsevier B.V. All rights reserved.
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The miRNAs and siRNAs were synthesized by GenePharma
(Shanghai, China). miRNA mimics are synthetic duplexes repre-
senting mature miRNAs. The oligonucleotide sequence of c-MET
siRNA was previously described [19]. siRNA and miRNA transfec-
tion was performed using HiperFect (QIAGEN). Twenty nanomolar
siRNA or miRNA was used for transfection in serum free medium.
Total RNA and protein were prepared 48–72 h after transfection
and further used for qPCR or Western blot analysis, respectively.
2.3. Quantitative analysis of miRNAs and mRNAs
Total RNA was extracted from cultured cells using TRIzol (Invit-
rogen) or miRVana miRNA Isolation Kit (Ambion) according to the
manufacturer’s protocols. The TaqMan stem-loop RT-PCR approach
was used to assess the expression of miRNAs with kits from Ap-
plied Biosystems. For quantitative analysis of c-MET expression,
100–200 ng of total RNA was used for synthesis of random-primed
single stranded cDNA using Primescript RT reagent kit (TaKaRa)
and cDNA was subjected to quantitative PCR using SYBR green
Master MIX (Applied Biosystem). The relative amount of gene
transcripts was normalized to GAPDH. The sequence of oligonucle-
otides used as PCR primers were: GAPDH (forward) 50-tgc acc acc
aac tgc tta gc-30, GAPDH (reverse) 50-ggc atg gac tgt ggt cat gag-
30; c-Met (forward) 50-gtt tgt cca cag aga ctt ggc tg-30, c-Met
(reverse) 50-atc cac ttc act ggc agc ttt g-30. Three independent
experiments were performed in triplicates.
2.4. Protein extraction and Western blot
Forty-eight hours after transfection, the cells were lysed using
cell lysis buffer (Cell Signaling). Protein concentration was deter-
mined with the BCA Protein Assay kit (Pierce) and equal amounts
of total proteins were separated in 10% SDS–polyacrylamide gels,
transferred to polyvinylidene diﬂuoride membranes (Bio-Rad).
Membranes were blocked for 1 h with 1% BSA in Tris-buffered sal-
ine containing 0.05% Tween 20, incubated overnight with primary
antibody, washed and incubated with secondary antibody, and
visualized by chemiluminescence. The antibodies used were as
follows: anti-c-MET antibody (sc-161; Santa Cruz), anti-b-Actin
(Abcam), anti-phospho-p44/42 MAPK and anti-p44/42 MAPK (Cell
Signaling).
2.5. Luciferase assay
The full-length 30UTR of c-MET was ampliﬁed and cloned down-
stream Renilla luciferase in a psiCHECK2 vector (Promega). Cells
plated on 24-well plates were transfected with 100 ng of psi-
CHECK2-C-MET-WT, psiCHECK2-C-MET-mut or psiCHECK2 and
200 nmol/l of miR-198 or negative control. After 48 h, cells were
lysed and assayed with Dual Luciferase Assay (Promega) according
to the manufacturer’s instructions. Three independent experi-
ments were performed in triplicate.
2.6. Cell proliferation
For determination of cell viability by MTT (3-(4,5-dic-METhyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, HepG2,
Hep3B or QGY-7701 cells (5  103) were suspended in DMEM/
F12 or DMEM containing 10% fetal bovine serum and cultured in
96-well plates. After transient transfection with negative control
oligonucleotides, miR-198 mimics or miR-198 ASO respectively
for 1 day, cells were serum starved for 24 h, then treated for 48 h
with HGF (20 ng/ml) and cell viability was evaluated using theMTT assay. The colorimetric assay was read at 570 nm in a
Microplate Reader (Model 3550 Bio-Rad). All experiments were
performed in triplicate and repeated trice. The data were plotted
as means ± S.D. of three separate experiments.
2.7. Cell migration and invasion assay
Assays were performed in BioCoat transwell chambers (Corning
Costar) with uncoated porous ﬁlters (pore size 8 lm) for estimation
of cell motility. Filters were precoated with matrigel for examina-
tion of cell invasion. Cells were serum deprived for 24 h before
experimentation. Cells were seeded on the upper chamber with
0.2% BSA dissolved in serum-free medium. HGF (20 ng/ml) was
added to the lower chamber as a chemoattractant for 12–24 h.
Filterswere ﬁxed in 90% ethanol and stainedwith 0.1% crystal violet
(Sigma) for counting. Values for cell migration or invasion were ex-
pressed as the average number of cells per microscopic ﬁeld over
three ﬁelds per one ﬁlter for triplicate experiments. Experiments
were repeated at least three times. All data are expressed as
mean ± S.D., and signiﬁcance was determined using Student’st-test.
2.8. Wound healing assay
Brieﬂy, HepG2, Hep3B or QGY-7701 cells were seeded in six-
well plates, cultured overnight, and transfected with negative
control oligonucleotides, miR-198 mimics, miR-198 ASO or c-
MET siRNA, respectively. Upon reaching appropriate conﬂuence,
cells were serum starved for 24 h, then the cell layer was scratched
with a sterile plastic tip and immediately washed twice with PBS
and cultured in DMEM/F-12 (serum free) or DMEM medium
(serum free) containing HGF (20 ng/ml) at 37 C in a humidiﬁed
incubator with 5% CO2. At different time points, photo images of
the plates were taken under a microscope.
3. Results
3.1. miR-198 binds to the 30UTR of c-MET mRNA
To identify downstream targets of miR-198, we performed bio-
informatics analysis by using three algorithms that predict the
mRNA targets of a particular miRNA—PicTar [20], TargetScan [21]
and the miRanda [22]. Seventeen putative target genes of miR-
198 were unanimously predicted by the three algorithms
(Fig. 1A). c-MET was of particular interest since its dysregulation
has been reported in many human malignancies and plays impor-
tant roles in tumor initiation and progression [3,4]. Using RNAhy-
brid [23], we located two potential binding sites for miR-198 at the
30UTR of the c-MET mRNA. These two sites were conserved across
different species (Fig. 1B and C) and two respective mutants were
further constructed (Fig. 1D). To conﬁrm the predictions in silico,
we cotransfected either a luciferase reporter gene fused to the c-
MET 30UTR or mutant c-MET 30UTR with miR-198 mimics or con-
trol oligonucleotides. Forced expression of miR-198 in HepG2 cells
signiﬁcantly reduced the activity of a luciferase reporter gene fused
to wild-type c-MET 30UTR by more than 50% (Fig. 1E). A single miR-
198 cognate binding site, LCS2, within the c-MET 30UTR, was iden-
tiﬁed as the major target site for miR-198 and thereby sufﬁcient to
regulate c-MET expression. These data suggest that miR-198 di-
rectly binds to the 30UTR of c-MET to regulate its expression.
3.2. Forced expression of miR-198 reduces c-MET expression
To verify if miR-198 expression affects the expression of c-MET
at both miRNA and protein levels, we transfected chemically
synthesized miR-198 mimics, miR-198 ASO or c-MET siRNA or
Fig. 1. miR-198 directly targets c-MET by interaction with its 30UTR. (A) Schema of the candidate genes predicted by different prediction methods. Each circle represents the
number of genes identiﬁed by one algorithm. Seventeen genes listed in the overlap of three circles are simultaneously predicted by different algorithms. (B) Predicted miR-
198 binding sites in the 30UTR of c-MET mRNA. c-MET 30UTR was marked with black color and speciﬁc locations of the binding sites were marked with gray color. (C)
Alignment of potential miR-198 binding site in the 30UTR of c-MET mRNA from different mammalian species. Seed sequences are in italics and underlined. (D) The sequences
of two predicted miR-198 binding sites within the 30UTR of c-MET and their cognate seed region. Mutations on the seed sequence are exhibited below the seed region. (E)
HepG2 cells were co-transfected with miR-198 mimics, plasmid reporter containing wild-type or mutant 30UTR of c-MET. After 48 h, luciferase assay was performed and
normalized to the internal ﬁreﬂy luciferase activity. ⁄P < 0.01.
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(HepG2, Hep3B and QGY-7701) as indicated (Fig. 2A). Based on the
endogenous expression levels of miR-198 in six different HCC cell
lines examined (Fig. S1A), we chose those cell lines with low
expression of miR-198 (HepG2 and Hep3B) for transfection of
miR-198 mimics (Fig. S1B). Correspondingly we chose those cells
with high expression of miR-198 (QGY-7701) for miRNA depletionFig. 2. Forced expression of miR-198 decreases c-MET expression and HGF stimulated p4
mimics or c-MET siRNA and QGY-7701 cells were transfected with either NC or miR-198
Actin. (B) HepG2 or Hep3B cells were transfected with miR-198 or c-MET siRNA and Q
treatment for 15 min. Western blot analysis was performed to detect phosphorylated pby transfection of miR-198 ASO (Fig. S1C). Forced expression of
miR-198 mimics signiﬁcantly reduced the expression of c-MET
protein in HepG2 and Hep3B cells, whereas the expression of
c-MET protein was up-regulated after forced expression of miR-
198 ASO in QGY-7701 (Fig. 2A). A speciﬁc siRNA targeting c-MET
was included as control. Interestingly, forced expression of miR-
198 potently diminished the expression of c-Met mRNA in Hep3B4/42 MAPK activity. (A) HepG2 and Hep3B cells were transfected with NC, miR-198
ASO. Western blot analysis was performed to detect the expression of c-MET or b-
GY-7701 cells were transfected with either NC or miR-198 ASO, followed by HGF
44/42 MAPK (P-p44/42 MAPK) or total p44/42 MAPK.
2232 S. Tan et al. / FEBS Letters 585 (2011) 2229–2234but not in HepG2 and QGY-7701 cells (Fig. S2A), suggesting that
miR-198 regulated expression of c-MET mRNA might employ a cell
context speciﬁc mechanism.
3.3. miR-198 effects on p44/42 MAPK activity via HGF/c-MET pathway
c-MET is considered essential for the invasive capacity of HCC
[4,5]. Upon the binding of its cognate ligand HGF, activated c-
MET triggers multiple signaling pathways including p44/42 MAPK
to promote cell migration and invasion [24,25]. To evaluate if the
observed altered expression of c-MET protein could inﬂuence
downstream signaling pathway, we ﬁrst assessed the phosphoryla-
tion status of p44/42 MAPK upon miR-198 expression. HGF-in-
duced p44/42 MAPK activation was determined after the cells
were treated with NC, miR-198 mimics or c-MET siRNA. Forced
expression of miR-198 resulted in a decreased activation of p44/
42 MAPK in both HepG2 and Hep3B cells (Fig. 2B), whereas deple-
tion of miR-198 expression by forced expression of speciﬁc ASO in-
creased p44/42 MAPK activity in QGY-7701 cells (Fig. 2B). These
data suggest that miR-198 expression could signiﬁcantly regulate
HGF-induced activation of p44/42 MAPK by targeting c-MET in
HCC cells.
3.4. Forced expression of miR-198 diminishes HGF promoted cell
motility
To better understand the functionality of miR-198 in HCC
progression, we tested whether miR-198 could exert an effect on
cell motility on HCC cells. HepG2, Hep3B or QGY-7701 cells wereFig. 3. Forced expression of miR-198 abrogates HGF stimulated cell motility. (A–C) HepG
198 ASO and then subject to wound healing assay in presence of HGF treatment for 24 h.
or miR-198 ASO and cell migration (D–F) and invasion (G–I) were determined by transwe
in triplicates with mean ± S.D., and representative images are displayed. ⁄P < 0.01.transfected with miR-198 mimics, c-MET siRNA or miR-198 ASO
and subsequently treated with 20 ng/ml of HGF before evaluation
of cell migration. We employed both wound healing assays and
transwell assays. Forced expression of miR-198 in HepG2 and
Hep3B cells led to a retarded closing of the wound compared to
control oligonucleotide transfected parental cells (Fig. 3A and B).
In comparison, depletion of miR-198 expression in QGY-7701 cells
led to a more rapid closing of the wound than control oligonucleo-
tide transfected parental cells (Fig. 3C). Concordantly, forced
expression of miR-198 signiﬁcantly diminished HGF stimulated
cell migration (Fig. 3D and E) and invasion (Fig. 3G and H) in
HepG2 and Hep3B cells. Depletion of endogenous c-MET by the
speciﬁc siRNA serves as positive controls. As expected, depletion
of miR-198 expression in QGY-7701 cells resulted in a dramatic de-
crease in HGF stimulated cell migration and invasion (Fig. 3F and I).
miR-198 has no effect on proliferation of HCC cells (Fig. S3). miR-
198 is therefore a negative regulator of migration and invasion of
HCC cells.
3.5. c-MET reintroduction restores miR-198-repressed cell motility
In order to determine the importance of c-MET as a functional
target of miR-198, we attempted to examine if forced expression
of c-MET could circumvent inhibitory effects of miR-198 on cell
motility. We thus constructed a lentiviral vector expressing
c-MET cDNA and demonstrated that c-MET expression was re-
stored after c-MET lentiviral infection (Fig. 4A). HCC cells were
transfected with miR-198 mimics or c-MET siRNA and treated with
20 ng/ml of HGF for evaluation of cell migration or invasion by use2, Hep3B and QGY-7701 cells were transfected with miR-198, c-MET siRNA or miR-
HepG2, Hep3B and QGY-7701 cells were transfected with NC, miR-198, c-MET siRNA
ll assay in presence of HGF treatment for 12–24 h. Transwell assays were performed
S. Tan et al. / FEBS Letters 585 (2011) 2229–2234 2233of transwell assay. We observed that forced expression of c-MET
rescued miR-198 repressed cell migration and invasion in presence
of HGF treatment (Fig. 4B and C). These ﬁndings show that forced
expression of c-MET could abrogate miR-198 induced repression of
cell motility in presence of HGF treatment. Thus c-MET is a func-
tionally relevant target downstream of miR-198 mediating the
migration and invasion of HCC cells.
4. Discussion
HCC is one of the most prevalent causes of cancer-related death
worldwide with an annual occurrence of more than 600 000 [1,2].
Tumor metastasis and disease recurrence are the major cause of
the poor prognosis of liver cancer patients. Thus identiﬁcation of
the molecular pathogenesis of HCC is important for the develop-
ment of effective therapeutic approaches leading to improve of
survival outcome of patients with this disease [26]. Emerging evi-
dence has reported that miR-198 is down-regulated in HCC com-
pared to normal liver [27]. However, the functional role of miR-
198 in HCC is largely unknown. To our knowledge, this is the ﬁrst
functional characterization as well as mechanistic study of miR-
198 in human cancer cells. In this study, our results demonstrated
that miR-198 is a potential metastasis suppressor for HCC as miR-
198 expression signiﬁcantly diminished HGF stimulated migrationFig. 4. Forced expression of c-MET restores miR-198 expression diminished HGF stimula
an empty vector or a lentivirus vector expressing c-MET cDNA and transfected with the
performed to detect expression of c-MET or b-Actin. HepG2 or Hep3B cells were infect
transfected with the indicated miR-198 mimics or control oligonucleotides. Transwell mig
Transwell assays were performed in triplicates with mean ± S.D., and representative imaand invasion of HCC cells. Utilizing bioinformatics analyses to
search for potential target genes of miR-198, we have identiﬁed
c-MET as one of the pivotal targets. We have subsequently mapped
two potential miR-198 binding sites in the 30UTR of c-MET mRNA
and further determined the critical site which is responsible for
the functional interaction with miR-198.
Among growth factors identiﬁed to be involved in HCC progres-
sion, the HGF/c-MET pathway has been demonstrated to play a key
role in growth, epithelial-mesenchymal transition, angiogenesis,
invasiveness and metastasis in of HCC cells [1,4,5]. c-MET has also
been reported to be essential for the metastatic potential of HCC
cells and represents as a powerful prognostic indicator for the early
stage of cancer invasion and metastasis [4,5,25]. As a result, multi-
ple c-MET pathway inhibitors are currently being evaluated in the
clinic [5]. Our data indicates that forced expression of miR-198
abrogated HGF stimulated p44/42MAPK activation and subsequent
cell migration and invasion by diminishing c-MET expression. It
should be of note that expression of miR-198 itself exerted no effect
on cell migration and invasion (data not shown), thus it should be
considered as a conditional metastasis suppressor in HCC. Future
efforts will be taken to determine whether miR-198 will impinge
on other signaling pathways involved in progression of HCC.
In conclusion, our study provides mechanistic insight of the
consequence of reduced expression of miR-198 in HCC cells andted cell migration and invasion. (A) HepG2 or Hep3B cells were infected with either
indicated miR-198 mimics or control oligonucleotides. Western blot analysis was
ed with either an empty vector or a lentivirus vector expressing c-MET cDNA and
ration assay (B) or invasion assay (C) were performed in presence of HGF treatment.
ges are displayed. ⁄P < 0.01.
2234 S. Tan et al. / FEBS Letters 585 (2011) 2229–2234its connection with HCC invasion. miR-198, as a conditional metas-
tasis suppressor in HCC cells, exerts its functional role by targeting
c-MET expression and consequent abrogation of HGF promoted
cancer cell invasion. These ﬁndings will facilitate a better under-
standing of the molecular pathogenesis of HCC and suggest that
reduction of miR-198 expression may be utilized as novel strategy
for HCC therapy.
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